Document:

EXHIBIT 4.20

 

NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH
THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE
IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO
AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH
SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED
IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON SHARE PURCHASE WARRANT

 

SENTIENT BRANDS HOLDINGS
INC.

 

Warrant Shares: 2,750,000

Date of Issuance: August 19, 2022 (“Issuance
Date”)

Holder: Adriatic Advisors, LLC, a New York limited
liability company (the “Holder”)

 

This COMMON SHARE PURCHASE WARRANT
(the “Warrant”) certifies that, for value received and in consideration for that certain Adriatic Stock Pledge and
Guaranty made by Holder in connection with the Company’s issuance to Leonite of the Leonite Notes pursuant to which Holder pledged
to Leonite the Pledged Shares and guaranteed the Leonite Notes, Holder is entitled, upon the terms and subject to the limitations on exercise
and the conditions hereinafter set forth, at any time on or after the Issuance Date, to purchase from Sentient Brands Holdings Inc., a
Nevada corporation (the ”Company”), 2,750,000 common shares (the “Warrant Shares”) (whereby
such number may be adjusted from time to time pursuant to the terms and conditions of this Warrant) at the Exercise Price per share then
in effect. This Warrant is issued by the Company as of the date hereof in connection with that certain agreement, dated August 19, 2022,
by and between the Company and the Holder (the “Agreement”).

 

Capitalized terms used in this
Warrant shall have the meanings set forth in the Agreement unless otherwise defined in the body of this Warrant or in Section 12 below.
For purposes of this Warrant, the term “Exercise Price” shall mean $0.60, subject to adjustment as provided herein
(including but not limited to cashless exercise), and the term ”Exercise Period” shall mean the period commencing
on the Issuance Date and ending on 6:00 p.m. eastern standard time on the five-year anniversary thereof.

 

1.             EXERCISE
OF WARRANT.

 

(a)          Mechanics
of Exercise. Subject to the terms and conditions hereof, the rights represented by this Warrant may be exercised in whole or in part
at any time or times during the Exercise Period by delivery of a written notice, in the form attached hereto as Exhibit A (the
“Exercise Notice”), of the Holder’s election to exercise this Warrant. The Holder shall not be required to deliver
the original Warrant in order to effect an exercise hereunder. Partial exercises of this Warrant resulting in purchases of a portion of
the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. On or before the fifth Trading Day (the “Warrant
Share Delivery Date”) following the date on which the Company shall have received the Exercise Notice, and upon receipt by the
Company of payment to the Company of an amount equal to the applicable Exercise Price multiplied by the number of Warrant Shares as to
which all or a portion of this Warrant is being exercised (the “Aggregate Exercise Price” and together with the Exercise
Notice,

 

     

     

    

 

the “Exercise Delivery Documents”) in cash or by wire transfer of immediately available funds (or by cashless
exercise, in which case there shall be no Aggregate Exercise Price provided), the Company shall direct its transfer agent to issue and
dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company’s share
register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such
exercise. Upon delivery of the Exercise Delivery Documents, the Holder shall be deemed for all corporate purposes to have become the holder
of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the certificates
evidencing such Warrant Shares. If this Warrant is submitted in connection with any exercise and the number of Warrant Shares represented
by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise, then the Company
shall as soon as practicable and in no event later than 30 days after any exercise and at its own expense, issue a new Warrant (in accordance
with Section 6) representing the right to purchase the number of Warrant Shares purchasable immediately prior to such exercise under this
Warrant, less the number of Warrant Shares with respect to which this Warrant is exercised.

 

If the Company fails to cause
its transfer agent to transmit to the Holder the respective Warrant Shares by the respective Warrant Share Delivery Date, then the Holder
will have the right to rescind such exercise in Holder’s sole discretion, and the Company shall pay to the Holder $250 per day in
cash, for each day beyond the Warrant Share Delivery Date that the Company fails to deliver such Warrant Shares.

 

If at any time after the 6 month
anniversary of the Issuance Date, the Market Price of one Common Share is greater than the Exercise Price and the Warrant Shares are not
registered under an effective non-stale registration statement of the Company, the Holder may elect to receive Warrant Shares pursuant
to a cashless exercise, in lieu of a cash exercise, equal to the value of this Warrant determined in the manner described below (or of
any portion thereof remaining unexercised) by surrender of this Warrant and a Notice of Exercise, in which event the Company shall issue
to Holder a number of Common Shares computed using the following formula:

 

X = Y (A-B)

 

A

 

Where X =        the number of Shares
to be issued to Holder.

 

Y =          the number of Warrant Shares that the Holder elects to purchase under this Warrant
(at the date of                 such calculation).

  

A =       the
Market Price (at the date of such calculation).

 

B =        Exercise
Price (as adjusted to the date of such calculation).

 

(b)           No
Fractional Shares. No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment pursuant
hereto. All Warrant Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining
whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance
of a fractional share, the Company may, in lieu of issuance of any fractional share rounded up to the next whole share, pay the Holder
otherwise entitled to such fraction a sum in cash equal to the product resulting from multiplying the then-current fair market value of
a Warrant Share by such fraction.

 

     2

     

    

  

(c)            Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, to the extent that after giving effect to issuance of Warrant Shares upon exercise as set forth on the applicable
Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other persons acting as a group together with the
Holder or any of the Holder’s Affiliates), would beneficially own in excess of the Beneficial Ownership Limitation, as defined below.
For purposes of the foregoing sentence, the number of Common Shares beneficially owned by the Holder and its Affiliates shall include
the number of Common Shares issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of Common Shares which would be issuable upon (i) exercise of the remaining, non-exercised portion of this Warrant beneficially
owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or non-converted portion of any other
securities of the Company (including without limitation any other Common Share Equivalents) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding
sentence, for purposes of this paragraph (d), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange
Act, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with
Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.
To the extent that the limitation contained in this paragraph applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any affiliates) and of which portion of this Warrant is exercisable shall be in
the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of
whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion
of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation
to verify or confirm the accuracy of such determination.

 

For purposes of this paragraph,
in determining the number of outstanding Common Shares, a Holder may rely on the number of outstanding Common Shares as reflected in (A)
the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement
by the Company or (C) a more recent written notice by the Company or its transfer agent setting forth the number of Common Shares outstanding.
Upon the request of a Holder, the Company shall within three Trading Days confirm to the Holder the number of Common Shares then outstanding.
In any case, the number of outstanding Common Shares shall be determined after giving effect to the conversion or exercise of securities
of the Company, including this Warrant, by the Holder or its affiliates since the date as of which such number of outstanding Common Shares
was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of Common Shares outstanding immediately
after giving effect to the issuance of Common Shares issuable upon exercise of this Warrant. Upon no fewer than 61 days’ prior notice
to the Company, a Holder may increase or decrease the Beneficial Ownership Limitation provisions of this paragraph and the provisions
of this paragraph shall continue to apply. Any such increase or decrease will not be effective until the 61st day after such notice is
delivered to the Company and shall only apply to such Holder and no other Holder. The limitations contained in this paragraph shall apply
to a successor Holder of this Warrant.

 

2.             ADJUSTMENTS.
The Exercise Price and the number of Warrant Shares shall be adjusted from time to time as follows:

 

(a)            Distribution
of Assets. If the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets)
to holders of Common Shares, by way of return of capital or otherwise (including without limitation any distribution of cash, shares or
other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement or other similar transaction)
(a “Distribution”), at any time after the issuance of this Warrant, then, in each such case:

 

     3

     

    

 

(i)       any
Exercise Price in effect immediately prior to the close of business on the record date fixed for the determination of holders of Common
Shares entitled to receive the Distribution shall be reduced, effective as of the close of business on such record date, to a price determined
by multiplying such Exercise Price by a fraction (i) the numerator of which shall be the Closing Sale Price of the Common Shares on the
Trading Day immediately preceding such record date minus the value of the Distribution (as determined in good faith by the Company’s
Board of Directors) applicable to one Common Share, and (ii) the denominator of which shall be the Closing Sale Price of the Common Shares
on the Trading Day immediately preceding such record date; and

 

(ii)       the
number of Warrant Shares shall be increased to a number of shares equal to the number of Common Shares obtainable immediately prior to
the close of business on the record date fixed for the determination of holders of Common Shares entitled to receive the Distribution
multiplied by the reciprocal of the fraction set forth in the immediately preceding clause (i); provided, however, that in the event that
the Distribution is of Common Shares of a company (other than the Company) whose common stock is traded on a national securities exchange
or a national automated quotation system (“Other Shares of Common Stock”), then the Holder may elect to receive a warrant
to purchase Other Shares of Common Stock in lieu of an increase in the number of Warrant Shares, the terms of which shall be identical
to those of this Warrant, except that such warrant shall be exercisable into the number of Other Shares of Common Stock that would have
been payable to the Holder pursuant to the Distribution had the Holder exercised this Warrant immediately prior to such record date and
with an aggregate exercise price equal to the product of the amount by which the exercise price of this Warrant was decreased with respect
to the Distribution pursuant to the terms of the immediately preceding clause (i) and the number of Warrant Shares calculated in accordance
with the first part of this clause (ii).

 

(b)           Proportional
Adjustments of Outstanding Common Shares and Common Share Dividends. If the Company shall at any time or from time to time after the
date hereof, issue additional Common Shares to all of its current shareholders on a pro rata basis or pay a share dividend in Common Shares,
then the Exercise Price shall be proportionately adjusted. Any adjustments under this Section 2(b) shall be effective at the close of
business on the date the share split becomes effective or the date of payment of the share dividend, as applicable. For the avoidance
of doubt, this adjustment shall not apply when shares of outstanding Common Share are merged proportionally across all shareholders to
form a smaller number of outstanding shares.

 

(c)           Anti-dilution
Adjustment. If at any time while this Warrant is outstanding, the Company sells or grants (or has sold or granted, as the case may
be) any option to purchase or sells or grants any right to reprice, or otherwise disposes of or issues (or has sold or issued, as the
case may be, or announces any sale, grant or any option to purchase or other disposition), any Common Share or other securities convertible
into, exercisable for or otherwise entitled the any person or entity the right to acquire Common Shares at an effective price per share
that is lower than the then Exercise Price (such lower price, the “Base Exercise Price” and such issuances, collectively,
a “Dilutive Issuance”) (it being agreed that if the holder of the Common Share or other securities so issued shall
at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or
otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to receive Common
Shares at an effective price per share that is lower than the Exercise Price, such issuance shall be deemed to have occurred for less
than the Exercise Price on such date of the Dilutive Issuance), then the Exercise Price shall be reduced to a price equal the Base Exercise
Price, and the number of Warrant Shares issuable hereunder shall be increased such that the aggregate Exercise Price payable hereunder,
after taking into account the decrease in the Exercise Price, shall be equal to the aggregate Exercise Price prior to such adjustment.
Such adjustment shall be made whenever such Common Share or other securities are issued, provided however, that no adjustment will be
made under this Section 2(c) in respect of an Exempt Issuance. For purposes of this Section 2(c), an “Exempt Issuance”
means an issuance of Common Shares or other securities convertible into or exercisable or exchangeable for Common Shares (i) upon the
exercise or exchange of any securities issued hereunder under the Warrant and/or other securities exercisable or exchangeable for or convertible
into Common Shares issued and outstanding on the date of this Warrant, (ii) to employees or directors of,

 

     4

     

    

 

or consultants or advisors to,
Company or any of its subsidiaries pursuant to a stock option plan of the Company, agreement or arrangement approved by the Board of Directors
of Company, (iii) to banks, equipment lessors or other financial institutions, or to real property lessors, pursuant to a debt financing,
equipment leasing or real property leasing transaction approved by the Board of Directors of Company, (iv) to suppliers or third party
service providers in connection with the provision of goods or services pursuant to transactions approved by the Board of Directors of
Company, (v) pursuant to the acquisition of another corporation or other entity by Company by merger, purchase of substantially all of
the assets or other reorganization or pursuant to a joint venture agreement, provided that such issuances are approved by the Board of
Directors of Company, (vi) to third parties in connection with collaboration, technology license, development, marketing or other similar
agreements or strategic partnerships approved by the Board of Directors of Company, or (vii) shares with respect to which the Holder waives
its anti-dilution rights granted hereby; provided, however, that any such issuance described in (iii) through (vi) shall only be to a
person (or to the equity holders of a person) which is, itself or through its subsidiaries, an employee, director, consultant or advisor,
in the case of (ii) above, or an operating company or an owner of an asset in a business synergistic with the business of Company in the
case of (iii) through (vi) above and shall provide to Company additional benefits in addition to the investment of funds, but in none
of (ii) through (vi) above shall not include a transaction in which Company is issuing securities primarily for the purpose of raising
capital or to an entity whose primary business is investing in securities.. In the event of an issuance of securities involving multiple
tranches or closings, any adjustment pursuant to this Section 2(c) shall be calculated as if all such securities were issued at the initial
closing.

 

3.             FUNDAMENTAL
TRANSACTIONS. If, at any time while this Warrant is outstanding, (i) the Company effects any merger of the Company with or into another
entity and the Company is not the surviving entity (such surviving entity, the “Successor Entity”), (ii) the Company
effects any sale of all or substantially all of its assets in one or a series of related transactions, (iii) any tender offer or exchange
offer (whether by the Company or by another individual or entity, and approved by the Company) is completed pursuant to which holders
of Common Shares are permitted to tender or exchange their Common Shares for other securities, cash or property and the holders of at
least 50% of the Common Shares accept such offer, or (iv) the Company effects any reclassification of the Common Shares or any compulsory
share exchange pursuant to which the Common Shares are effectively converted into or exchanged for other securities, cash or property
(other than as a result of a subdivision or combination of Common Shares) (in any such case, a “Fundamental Transaction”),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive the number of Common Shares of the Successor
Entity or of the Company and any additional consideration (the “Alternate Consideration”) receivable upon or as a result
of such reorganization, reclassification, merger, consolidation or disposition of assets by a holder of the number of Common Shares for
which this Warrant is exercisable immediately prior to such event (disregarding any limitation on exercise contained herein solely for
the purpose of such determination). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one Common Share
in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Shares are given
any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same
choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. To the
extent necessary to effectuate the foregoing provisions, any Successor Entity in such Fundamental Transaction shall issue to the Holder
a new warrant consistent with the foregoing provisions and evidencing the Holder’s right to exercise such warrant into Alternate
Consideration.

 

4.             NON-CIRCUMVENTION.
The Company covenants and agrees that it will not, by amendment of its certificate of formation, operating agreement or through any reorganization,
transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out
all the provisions of this Warrant and take all action as may be required to protect the rights of the Holder. Without limiting the generality
of the foregoing, the Company (i) shall not increase the par value of any Common Shares receivable upon the exercise of this Warrant above
the Exercise Price then in effect, (ii) shall take all such actions as may be necessary or appropriate in order that the Company may validly
and legally issue fully paid and non-assessable Common Shares upon the exercise of this Warrant, and (iii) shall, for so long as this
Warrant is outstanding, have authorized and reserved, free from preemptive rights, a sufficient number of Common Shares to provide for
the exercise of the rights represented by this Warrant (without regard to any limitations on exercise).

 

     5

     

    

 

5.             WARRANT
HOLDER NOT DEEMED A SHAREHOLDER. Except as otherwise specifically provided herein, this Warrant, in and of itself, shall not entitle
the Holder to any voting rights or other rights as a shareholder of the Company. In addition, nothing contained in this Warrant shall
be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a
shareholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.

 

6.             REISSUANCE.

 

(a)            Lost,
Stolen or Mutilated Warrant. If this Warrant is lost, stolen, mutilated or destroyed, the Company will, on such terms as to indemnity
or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new
Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed.

 

(b)           Issuance
of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant shall
be of like tenor with this Warrant, and shall have an issuance date, as indicated on the face of such new Warrant which is the same as
the Issuance Date.

 

7.             TRANSFER.

 

(a)            Notice
of Transfer. The Holder agrees that it will give written notice to the Company of its intent to transfer this Warrant or any Warrant
Shares, describing briefly the manner of any proposed transfer. Promptly upon receiving such written notice, the Company shall present
copies thereof to the Company’s counsel. If the proposed transfer may be effected without registration or qualification (under any
federal or state securities laws), the Company, as promptly as practicable, shall notify the Holder thereof, whereupon the Holder shall
be entitled to transfer this Warrant or to dispose of Warrant Shares received upon the previous exercise of this Warrant, all in accordance
with the terms of the notice delivered by the Holder to the Company; provided, however, that an appropriate legend may be endorsed on
this Warrant or the certificates for such Warrant Shares respecting restrictions upon transfer thereof necessary or advisable in the opinion
of counsel and satisfactory to the Company to prevent further transfers which would be in violation of Section 5 of the Securities Act
and applicable state securities laws; and provided further that the prospective transferee or purchaser shall execute the Assignment of
Warrant attached hereto as Exhibit B and such other documents and make such representations, warranties, and agreements as may
be required solely to comply with the exemptions relied upon by the Company for the transfer or disposition of the Warrant or Warrant
Shares.

 

(b)           If
the proposed transfer or disposition of this Warrant or such Warrant Shares described in the written notice given pursuant to this Section
7 may not be effected without registration or qualification of this Warrant or such Warrant Shares, the Holder will limit its activities
in respect to such transfer or disposition as are permitted by law.

 

(c)            Any
transferee of all or a portion of this Warrant shall succeed to the rights and benefits of the initial Holder of this Warrant.

 

8.             NOTICES.
Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given in accordance
with the notice provisions contained in the Agreement. The Company shall provide the Holder with prompt written notice (i) immediately
upon any adjustment of the Exercise Price, setting forth in reasonable detail, the calculation of such adjustment and (ii) at least 20
days prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend or distribution upon the
Common Shares, (B) with respect to any grants, issuances or sales of any shares or other securities directly or indirectly convertible
into or exercisable or exchangeable for Common Shares or other property, pro rata to the holders of Common Shares or (C) for determining
rights to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case that such information shall
be made known to the public prior to or in conjunction with such notice being provided to the Holder.

 

     6

     

    

 

9.             AMENDMENT
AND WAIVER. The terms of this Warrant may be amended or waived (either generally or in a particular instance and either retroactively
or prospectively) only with the written consent of the Company and the Holder.

 

10.           GOVERNING
LAW. This Warrant shall be governed by and construed in accordance with the laws of the State of Nevada without regard to principles
of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated by this Warrant shall
be brought only in the state courts or federal courts sitting in Nevada. The parties to this Warrant hereby irrevocably waive any objection
to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or
based upon forum non conveniens. THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST,
A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS WARRANT OR ANY TRANSACTION CONTEMPLATED
HEREBY. The prevailing party shall be entitled to recover from the other party its reasonable attorney’s fees and costs. In
the event that any provision of this Warrant or any other agreement delivered in connection herewith is invalid or unenforceable under
any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and
shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under
any law shall not affect the validity or enforceability of any other provision of any agreement. Each party hereby irrevocably waives
personal service of process and consents to process being served in any suit, action or proceeding in connection with this Agreement or
any other Transaction Document by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law.

 

11.           ACCEPTANCE.
Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.

 

12.           CERTAIN
DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings:

 

(a)           “Nasdaq”
means The Nasdaq Stock Market (www.Nasdaq.com).

 

(b)           “Closing
Sale Price” means, for any security as of any date, (i) the last closing trade price for such security on the Principal Market,
as reported by Nasdaq, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing trade
price, then the last trade price of such security prior to 4:00 p.m., New York time, as reported by Nasdaq, or (ii) if the foregoing
does not apply, the last trade price of such security in the over-the-counter market for such security as reported by Nasdaq, or (iii)
if no last trade price is reported for such security by Nasdaq, the average of the bid and ask prices of any market makers for such security
as reported by the OTC Markets or any other similar domestic or foreign exchange. If the Closing Sale Price cannot be calculated for a
security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market
value as mutually determined by the Company and the Holder. All such determinations to be appropriately adjusted for any share dividend,
share split, share combination or other similar transaction during the applicable calculation period.

 

     7

     

    

 

(c)            “Common
Share” means the Common Shares of the Company and any other class of securities into which such securities may hereafter be
reclassified or changed.

 

(d)           “Common
Share Equivalents” means any securities of the Company that would entitle the holder thereof to acquire at any time Common Shares,
including without limitation any debt, preferred shares, rights, options, warrants or other instrument that is at any time convertible
into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Shares.

 

(e)            “Principal
Market” means the primary national securities exchange or over the counter market on which the Common Shares are then traded.

 

(f)            “Market
Price” means the highest traded price of the Common Shares during the thirty (30) Trading Days prior to the date of the respective
Exercise Notice.

 

(g)           “Trading
Day” means (i) any day on which the Common Shares are listed or quoted and traded on its Principal Market, (ii) if the Common
Shares are not then listed or quoted and traded on any national securities exchange, then a day on which trading occurs on any over-the-counter
markets, or (iii) if trading does not occur on the over-the-counter markets, any Business Day.

 

[signature page follows]

 

     8

     

    

 

IN WITNESS WHEREOF, the Company
has caused this Warrant to be duly executed as of the Issuance Date set forth above.

 

	 	SENTIENT BRANDS HOLDINGS INC.
	 	 
	 	By: /s/ Dante Jones
	 	Name: Dante Jones
	 	Title: Interim Chief Executive Officer

  

     

     

    

 

EXHIBIT A

 

EXERCISE
NOTICE

 

(To
be executed by the registered holder to exercise this Common Share Purchase Warrant)

 

The
Undersigned holder hereby exercises the right to purchase _________________
of the Common Shares (“Warrant Shares”) of SENTIENT BRANDS HOLDINGS INC., a Nevada corporation (the “Company”),
evidenced by the attached copy of the Common Share Purchase Warrant (the ”Warrant”). Capitalized terms used herein and
not otherwise defined shall have the respective meanings set forth in the Warrant.

 

		1.	Form
                                            of Exercise Price. The Holder intends that payment of the Exercise Price shall be made
                                            as (check one):

 

☐
a cash exercise with respect to _________________ Warrant Shares; or

 

☐
by cashless exercise pursuant to the Warrant.

 

		2.	Payment
                                            of Exercise Price. If cash exercise is selected above, the holder shall pay the applicable
                                            Aggregate Exercise Price in the sum of $___________________ to the Company in accordance
                                            with the terms of the Warrant.

 

		3.	Delivery
                                            of Warrant Shares. The Company shall deliver to the holder __________________ Warrant
                                            Shares in accordance with the terms of the Warrant.

 

	Date: ______________________________	 
	 	________________________________________________
	 	(Print Name of Registered Holder)
	 	 
	 	By:________________________________________
	 	Name:______________________________________
	 	Title:_______________________________________

 

     

     

    

 

EXHIBIT B

 

ASSIGNMENT OF WARRANT

 

(To be signed only upon authorized transfer of the
Warrant)

 

For
Value Received, the undersigned hereby sells, assigns, and transfers unto ____________________ the right to purchase _______________
Common Shares of SENTIENT BRANDS HOLDINGS INC., to which the within Common Share Purchase Warrant relates and appoints ____________________,
as attorney-in-fact, to transfer said right on the books of Sentient Brands Holdings Inc. with full power of substitution and re-substitution
in the premises. By accepting such transfer, the transferee has agreed to be bound in all respects by the terms and conditions of the
within Warrant.

 

	Dated:__________________	 
	 	 
	 	(Signature) *
	 	 
	 	(Name)
	 	 
	 	(Address)
	 	 
	 	(Social Security or Tax Identification No.)

  

* The signature on this Assignment of Warrant must
correspond to the name as written upon the face of the Common Share Purchase Warrant in every particular without alteration or enlargement
or any change whatsoever. When signing on behalf of a corporation, partnership, trust or other entity, please indicate your position(s)
and title(s) with such entity.EXHIBIT 4.21

 

AGREEMENT

 

This AGREEMENT (this “Agreement”),
dated as of August 19, 2022, by and among Sentient Brands Holdings Inc., a Nevada corporation, with headquarters located at 590 Madison
Avenue, 21st Floor, New York, NY 10022 (the “Company”), and Adriatic Advisors, LLC, a New York limited liability
company, located at 111 East 14th Street, Suite 286, New York, NY 10003 (the “Holder”).

 

WHEREAS:

 

A.           The
Company and Holder are executing and delivering this Agreement in reliance upon an exemption from securities registration afforded by
Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”), and/or Regulation D as promulgated by the
United States Securities and Exchange Commission (the “SEC”); and

 

B.           Company
wishes to issue to the Holder, in consideration for that certain stock pledge and guaranty made by Holder (the “Adriatic Stock
Pledge and Guaranty”) to Leonite Fund I LLC (“Leonite”), in connection with the Company’s issuance
to Leonite of those certain senior secured convertible promissory notes dated April 27, 2021 and November 18, 2021, respectively (the
“Leonite Notes”), pursuant to which Holder pledged to Leonite 2,752,040 shares of common stock of Nukkleus Inc. held
by Holder (the “Pledged Shares”), a Common Share Purchase Warrant, in the form attached hereto as Exhibit A,
to purchase shares of the Company’s common stock exercisable for five (5) years at an exercise price of $0.60 per share (the “Warrant”),
which shall be issued to Holder of even date herewith and as further provided herein.

 

NOW THEREFORE, the Company and Holder hereby
agree as follows:

 

1.             TERMS
OF THE WARRANT.

 

a.       Issuance
of the Warrant. Subject to the terms of this Agreement, for value received by the Company and in consideration for the Adriatic
Stock Pledge and Guaranty made by Holder in connection with the Company’s issuance to Leonite of the Leonite Notes pursuant to which
Holder pledged to Leonite the Pledged Shares and guaranteed the Leonite Notes, on the Issuance Date, the Company shall issue to Holder
the Warrant pursuant to which Holder is entitled, at any time on or after the date of issuance of the Warrant to Holder, to purchase from
the Company 2,750,000 common shares (the “Warrant Shares”) (whereby such number may be adjusted from time to time pursuant
to the terms and conditions of the Warrant) at the Exercise Price per share then in effect. For purposes
of the Warrant, the term “Exercise Price” shall mean $0.60, subject to adjustment as provided therein (including but not limited
to cashless exercise), and the term “Exercise Period” shall mean the period commencing on the Issuance Date and ending on
6:00 p.m. eastern standard time on the five-year anniversary thereof. Capitalized terms used in this Agreement shall have the meanings
set forth in the Warrant unless otherwise defined in the body of this Agreement.

 

b.       Delivery
of Warrant. On the Issuance Date, the Company shall issue and deliver the Warrant duly executed on behalf of the Company to Holder.

 

     

     

    

 

c.       Issuance
Date. The Issuance Date shall have the meaning set forth in the Warrant.

 

2.             HOLDERS’
REPRESENTATIONS AND WARRANTIES. The Holder represents and warrants to the Company solely as to such Holder that:

 

a.       Investment
Purpose. As of the date hereof, the Holder is receiving the shares of common stock issuable upon exercise of or otherwise pursuant
to the Warrant (such shares of common stock being collectively referred to herein as the “Warrant Shares” and, collectively
with the Warrant and Warrant Shares, the “Securities”) for its own account and not with a present view towards the
public sale or distribution thereof, except pursuant to sales registered or exempted from registration under the 1933 Act.

 

b.       Accredited
Investor Status. The Holder is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D (an
“Accredited Investor”).

 

c.       Reliance
on Exemptions. The Holder understands that the Securities are being offered and sold to it in reliance upon specific exemptions
from the registration requirements of United States federal and state securities laws and that the Company is relying upon the truth and
accuracy of, and the Holder’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of
the Holder set forth herein in order to determine the availability of such exemptions and the eligibility of the Holder to acquire the
Securities.

 

d.       Governmental
Review. The Holder understands that no United States federal or state agency or any other government or governmental agency has
passed upon or made any recommendation or endorsement of the Securities.

 

e.       Transfer
or Re-sale. The Holder understands that (i) the sale or re-sale of the Securities has not been and is not being registered under
the 1933 Act or any applicable state securities laws, and the Securities may not be transferred unless (a) the Securities are sold pursuant
to an effective registration statement under the 1933 Act, (b) the Holder shall have delivered to the Company an opinion of counsel that
shall be in form, substance and scope customary for opinions of counsel in comparable transactions to the effect that the Securities to
be sold or transferred may be sold or transferred pursuant to an exemption from such registration, which opinion shall be accepted by
the Company, (c) the Securities are sold or transferred to an “affiliate” (as defined in Rule 144 promulgated under the 1933
Act (or a successor rule) (“Rule 144”)) of the Holder who agrees to sell or otherwise transfer the Securities only
in accordance with this Section 2(e) and who is an Accredited Investor, (d) the Securities are sold pursuant to Rule 144, or (e) the Securities
are sold pursuant to Regulation S under the 1933 Act (or a successor rule) (“Regulation S”), and the Holder shall have
delivered to the Company an opinion of counsel that shall be in form, substance and scope customary for opinions of counsel in corporate
transactions, which opinion shall be accepted by the Company; (ii) any sale of such Securities made in reliance on Rule 144 may be made
only in accordance with the terms of said Rule and further, if said Rule is not applicable, any re-sale of such Securities under circumstances
in which the seller (or the person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933
Act) may require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC thereunder; and (iii)
neither the Company nor any other person is under any obligation to register such Securities under the 1933 Act or any state securities
laws or to comply with the terms and conditions of any exemption thereunder. Notwithstanding the foregoing or anything else contained
herein to the contrary, the Securities may be pledged as collateral in connection with a bona fide margin account or other lending
arrangement.

 

    2 

     

    

 

f.       Legends.
The Holder understands that the Warrant and, until such time as the Warrant Shares have been registered under the 1933 Act or otherwise
may be sold pursuant to Rule 144 or Regulation S without any restriction as to the number of securities as of a particular date that can
then be immediately sold, the Warrant Shares may bear a restrictive legend in substantially the following form (and a stop-transfer order
may be placed against transfer of the certificates for such Securities):

 

“The securities represented by this certificate have not been
registered under the Securities Act of 1933, as amended. The securities may not be sold, transferred or assigned in the absence of an
effective registration statement for the securities under said Act, or an opinion of counsel, in form, substance and scope customary for
opinions of counsel in comparable transactions, that registration is not required under said Act or unless sold pursuant to Rule 144 or
Regulation S under said Act.”

 

The legend set forth above shall be removed and the
Company shall issue a certificate without such legend to the holder of any Security upon which it is stamped, if, unless otherwise required
by applicable state securities laws, (a) such Security is registered for sale under an effective registration statement filed under the
1933 Act or otherwise may be sold pursuant to Rule 144 or Regulation S without any restriction as to the number of securities as of a
particular date that can then be immediately sold, or (b) such holder provides the Company with an opinion of counsel, in form, substance
and scope customary for opinions of counsel in comparable transactions, to the effect that a public sale or transfer of such Security
may be made without registration under the 1933 Act, which opinion shall be accepted by the Company so that the sale or transfer is effected
or (c) such holder provides the Company with reasonable assurances that such Security can be sold pursuant to Rule 144 or Regulation S.
The Holder agrees to sell all Securities, including those represented by a certificate(s) from which the legend has been removed, in compliance
with applicable prospectus delivery requirements, if any.

 

g.       Authorization;
Enforcement. This Agreement has been duly and validly authorized. This Agreement has been duly executed and delivered on behalf
of the Holder, and this Agreement constitutes valid and binding agreements of the Holder enforceable in accordance with their terms.

 

h.       Residency.
The Holder is a resident of the jurisdiction set forth on the first page hereto.

 

    3 

     

    

 

3.             REPRESENTATIONS
AND WARRANTIES OF THE COMPANY. The Company represents and warrants to Holder that:

 

a.       Organization
and Qualification. The Company and each of its subsidiaries, if any, is a corporation duly organized, validly existing and in
good standing under the laws of the jurisdiction in which it is incorporated, with full power and authority (corporate and other) to own,
lease, use and operate its properties and to carry on its business as and where now owned, leased, used, operated and conducted.

 

b.       Authorization;
Enforcement. The Company has all requisite corporate power and authority to enter into and perform this Agreement.

 

c.       Capitalization.
The capitalization of the Company is as set forth in the Company’s reports as filed with the Securities and Exchange Commission.

 

d.       Issuance
of Shares. The Warrant Shares are duly authorized and reserved for issuance and, upon exercise of the Warrant.

 

e.       Acknowledgment
of Dilution. The Company understands and acknowledges the potentially dilutive effect to the common stock upon the issuance of
the Warrant Shares.

 

4.            COVENANTS.

 

a.       Best
Efforts. The parties shall use their best efforts to satisfy timely each of the conditions described in this Agreement.

 

b.       Blue
Sky Laws. The Company shall, on or before the Issuance Date, take such action as the Company shall reasonably determine is necessary
to qualify the Securities for sale to the Holder at the applicable closing pursuant to this Agreement under applicable securities or “blue
sky” laws of the states of the United States (or to obtain an exemption from such qualification), and shall provide evidence of
any such action so taken to Holder on or prior to the Issuance Date.

 

5.            INTENTIONALLY
LEFT BLANK.

 

6.            INTENTIONALLY
LEFT BLANK.

 

7.            INTENTIONALLY
LEFT BLANK.

 

    4 

     

    

 

8.            GOVERNING
LAW; MISCELLANEOUS.

 

a.       Governing
Law. THIS AGREEMENT SHALL BE ENFORCED, GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEVADA APPLICABLE
TO AGREEMENTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD TO THE PRINCIPLES OF CONFLICT OF LAWS. THE PARTIES HERETO
HEREBY SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE UNITED STATES FEDERAL COURTS LOCATED IN NEW YORK, NEW YORK WITH RESPECT TO ANY DISPUTE
ARISING UNDER THIS AGREEMENT, THE AGREEMENTS ENTERED INTO IN CONNECTION HEREWITH OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. BOTH
PARTIES IRREVOCABLY WAIVE THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH SUIT OR PROCEEDING. BOTH PARTIES FURTHER AGREE
THAT SERVICE OF PROCESS UPON A PARTY MAILED BY FIRST CLASS MAIL SHALL BE DEEMED IN EVERY RESPECT EFFECTIVE SERVICE OF PROCESS UPON THE
PARTY IN ANY SUCH SUIT OR PROCEEDING. NOTHING HEREIN SHALL AFFECT EITHER PARTY’S RIGHT TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED
BY LAW. BOTH PARTIES AGREE THAT A FINAL NON-APPEALABLE JUDGMENT IN ANY SUCH SUIT OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED
IN OTHER JURISDICTIONS BY SUIT ON SUCH JUDGMENT OR IN ANY OTHER LAWFUL MANNER. THE PARTY WHICH DOES NOT PREVAIL IN ANY DISPUTE ARISING
UNDER THIS AGREEMENT SHALL BE RESPONSIBLE FOR ALL FEES AND EXPENSES, INCLUDING ATTORNEYS’ FEES, INCURRED BY THE PREVAILING PARTY
IN CONNECTION WITH SUCH DISPUTE.

 

b.       Counterparts;
Signatures by Facsimile. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original
but all of which shall constitute one and the same agreement and shall become effective when counterparts have been signed by each party
and delivered to the other party. This Agreement, once executed by a party, may be delivered to the other party hereto by facsimile transmission
of a copy of this Agreement bearing the signature of the party so delivering this Agreement.

 

c.       Headings.
The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the interpretation of, this
Agreement.

 

d.       Severability.
In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision
shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or
rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability
of any other provision hereof.

 

e.       Entire
Agreement; Amendments. This Agreement and the instruments referenced herein contain the entire understanding of the parties with
respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the
Holder makes any representation, warranty, covenant or undertaking with respect to such matters. No provision of this Agreement may be
waived or amended other than by an instrument in writing signed by the party to be charged with enforcement.

 

f.       Notices.
Any notices required or permitted to be given under the terms of this Agreement shall be sent by certified or registered mail (return
receipt requested) or delivered personally or by courier (including a recognized overnight delivery service) or by facsimile and shall
be effective five days after being placed in the mail, if mailed by regular United States mail, or upon receipt, if delivered personally
or by courier (including a recognized overnight delivery service) or by facsimile, in each case addressed to a party. The addresses for
such communications shall be:

 

    5 

     

    

 

If to the Holder, to the address set forth in the introductory
paragraph on the first page hereto.

 

	If to the Company, to:	Sentient Brands Holdings Inc.
	 	590 Madison Avenue, 21st Floor
	 	New York, NY 10022
	 	Attention: Dante Jones
	 	Telephone: 646-202-2897
	 	Email: dante@sentientbrands.com

  

	With a copy to:	Costaldo Law Group P.C.
	 	Attn: Evan Costaldo, Esq.
	 	30 Wall Street, 8th floor
	 	New York, NY 10005
	 	 

Each party shall provide notice to the other party of any change in address.

 

g.       Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns. Neither
the Company nor Holder shall assign this Agreement or any rights or obligations hereunder without the prior written consent of the other.
Notwithstanding the foregoing, subject to Section 2(f), Holder may assign its rights hereunder to any person that purchases Securities
in a private transaction from a Holder or to any of its “affiliates,” as that term is defined under the 1934 Act, without
the consent of the Company.

 

h.       Third
Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

    6 

     

    

 

IN WITNESS WHEREOF, the undersigned parties
have caused this Agreement to be duly executed as of the date first above written.

 

SENTIENT BRANDS HOLDINGS INC.

 

	/s/ Dante Jones	 
	Dante Jones	 
	Chief Executive Officer	 

 

ADRIATIC ADVISORS, LLC

 

	/s/ Jelena Vadanjel	 
	Jelena Vadanjel	 
	Managing Member	 

 

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]